Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

TOP: Trial of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis

This study has been completed.
Information provided by:
NPS Pharmaceuticals Identifier:
First received: September 9, 2005
Last updated: January 20, 2009
Last verified: September 2005
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: November 2003
  Estimated Primary Completion Date: No date given
No publications provided by NPS Pharmaceuticals

Publications automatically indexed to this study by Identifier (NCT Number):